Arti D Shah1, Edward C Hsiao1, Betsy O'Donnell1, Kirsten Salmeen1, Robert Nussbaum1, Michael Krebs1, Sabina Baumgartner-Parzer1, Martin Kaufmann1, Glenville Jones1, Daniel D Bikle1, YongMei Wang1, Allen S Mathew1, Dolores Shoback1, Ingrid Block-Kurbisch1. 1. Division of Endocrinology, Department of Medicine (A.D.S., E.C.H., D.S., I.B.K.), Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences (B.O., K.S.), and Division of Medical Genetics, Department of Medicine (R.N.), University of California, San Francisco, San Francisco, California 94143; Division of Endocrinology and Metabolism (M.Kr., S.B.-P.), Medical University of Vienna, A-1090 Vienna, Austria; Department of Biomedical and Molecular Sciences (M.Ka., G.J.), Queen's University, Kingston, Ontario, Canada K7L 3N6; Endocrine Research Unit (D.D.B., Y.M., D.S.), San Francisco Department of Veterans Affairs Medical Center; San Francisco, California 94121; and Redwood Renal Associates (A.S.M.), Eureka, California 95501.
Abstract
CONTEXT: Calcium metabolism changes in pregnancy and lactation to meet fetal needs, with increases in 1,25-dihydroxyvitamin D [1,25-(OH)2D] during pregnancy playing an important role. However, these changes rarely cause maternal hypercalcemia. When maternal hypercalcemia occurs, further investigation is essential, and disorders of 1,25-(OH)2D catabolism should be carefully considered in the differential diagnosis. CASE: A patient with a childhood history of recurrent renal stone disease and hypercalciuria presented with recurrent hypercalcemia and elevated 1,25-(OH)2D levels during pregnancy. Laboratory tests in the fourth pregnancy showed suppressed PTH, elevated 1,25-(OH)2D, and high-normal 25-hydroxyvitamin D levels, suggesting disordered vitamin D metabolism. Analysis revealed low 24,25-dihydroxyvitamin D3 and high 25-hydroxyvitamin D3 levels, suggesting loss of function of CYP24A1 (25-hydroxyvitamin-D3-24-hydroxylase). Gene sequencing confirmed that she was a compound heterozygote with the E143del and R396W mutations in CYP24A1. CONCLUSIONS: This case broadens presentations of CYP24A1 mutations and hypercalcemia in pregnancy. Furthermore, it illustrates that patients with CYP24A1 mutations can maintain normal calcium levels during the steady state but can develop hypercalcemia when challenged, such as in pregnancy when 1,25-(OH)2D levels are physiologically elevated.
CONTEXT: Calcium metabolism changes in pregnancy and lactation to meet fetal needs, with increases in 1,25-dihydroxyvitamin D [1,25-(OH)2D] during pregnancy playing an important role. However, these changes rarely cause maternal hypercalcemia. When maternal hypercalcemia occurs, further investigation is essential, and disorders of 1,25-(OH)2D catabolism should be carefully considered in the differential diagnosis. CASE: A patient with a childhood history of recurrent renal stone disease and hypercalciuria presented with recurrent hypercalcemia and elevated 1,25-(OH)2D levels during pregnancy. Laboratory tests in the fourth pregnancy showed suppressed PTH, elevated 1,25-(OH)2D, and high-normal 25-hydroxyvitamin D levels, suggesting disorderedvitamin D metabolism. Analysis revealed low 24,25-dihydroxyvitamin D3 and high 25-hydroxyvitamin D3 levels, suggesting loss of function of CYP24A1 (25-hydroxyvitamin-D3-24-hydroxylase). Gene sequencing confirmed that she was a compound heterozygote with the E143del and R396W mutations in CYP24A1. CONCLUSIONS: This case broadens presentations of CYP24A1 mutations and hypercalcemia in pregnancy. Furthermore, it illustrates that patients with CYP24A1 mutations can maintain normal calcium levels during the steady state but can develop hypercalcemia when challenged, such as in pregnancy when 1,25-(OH)2D levels are physiologically elevated.
Authors: R St-Arnaud; A Arabian; R Travers; F Barletta; M Raval-Pandya; K Chapin; J Depovere; C Mathieu; S Christakos; M B Demay; F H Glorieux Journal: Endocrinology Date: 2000-07 Impact factor: 4.736
Authors: Karl P Schlingmann; Martin Kaufmann; Stefanie Weber; Andrew Irwin; Caroline Goos; Ulrike John; Joachim Misselwitz; Günter Klaus; Eberhard Kuwertz-Bröking; Henry Fehrenbach; Anne M Wingen; Tülay Güran; Joost G Hoenderop; René J Bindels; David E Prosser; Glenville Jones; Martin Konrad Journal: N Engl J Med Date: 2011-06-15 Impact factor: 91.245
Authors: Martin Kaufmann; J Christopher Gallagher; Munro Peacock; Karl-Peter Schlingmann; Martin Konrad; Hector F DeLuca; Rita Sigueiro; Borja Lopez; Antonio Mourino; Miguel Maestro; René St-Arnaud; Joel S Finkelstein; Donald P Cooper; Glenville Jones Journal: J Clin Endocrinol Metab Date: 2014-03-26 Impact factor: 5.958
Authors: Sonoko Masuda; Valarie Byford; Alice Arabian; Yoshiyuki Sakai; Marie B Demay; René St-Arnaud; Glenville Jones Journal: Endocrinology Date: 2004-10-21 Impact factor: 4.736
Authors: Mandy E Turner; Christine A White; Sarah M Taylor; Kathryn Neville; Karen Rees-Milton; Wilma M Hopman; Michael A Adams; Tassos Anastassiades; Rachel M Holden Journal: Calcif Tissue Int Date: 2021-01-22 Impact factor: 4.333
Authors: Gina N Woods; Alec Saitman; Hanlin Gao; Nigel J Clarke; Robert L Fitzgerald; Nai-Wen Chi Journal: J Bone Miner Res Date: 2016-05-06 Impact factor: 6.741
Authors: J A Tamblyn; R Susarla; C Jenkinson; L E Jeffery; O Ohizua; R F Chun; S Y Chan; M D Kilby; M Hewison Journal: Placenta Date: 2016-12-18 Impact factor: 3.481
Authors: Nina Lenherr-Taube; Edwin J Young; Michelle Furman; Yesmino Elia; Esther Assor; David Chitayat; Tami Uster; Susan Kirwin; Katherine Robbins; Kathleen M B Vinette; Alan Daneman; Christian R Marshall; Carol Collins; Kenneth Thummel; Etienne Sochett; Michael A Levine Journal: J Clin Endocrinol Metab Date: 2021-09-27 Impact factor: 6.134
Authors: K Berit Sellars; Brittany A Ryan; Sarah A Hartery; Beth J Kirby; Christopher S Kovacs Journal: Endocrinology Date: 2021-01-01 Impact factor: 5.051
Authors: Tomás P Griffin; Caroline M Joyce; Sumaya Alkanderi; Liam M Blake; Derek T O'Keeffe; Delia Bogdanet; Md Nahidul Islam; Michael C Dennedy; John E Gillan; John J Morrison; Timothy O'Brien; John A Sayer; Marcia Bell; Paula M O'Shea Journal: Endocr Connect Date: 2020-06 Impact factor: 3.335